
|Videos|May 22, 2021
Neoadjuvant Therapy for HR+ Breast Cancer
Author(s)Kevin Kalinsky, MD, MS
Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
5































































